Please join us for a presentation with Dr. Doug Kerr, Chief Medical Officer at Dyne Therapeutics. Dr. Kerr will share topline results from the DELIVER clinical trial, along with new long-term data showing sustained benefits out to 24 months. DELIVER is Dyne’s global, randomized, placebo-controlled, double-blind, Phase 1/2 trial that evaluated the safety, tolerability and efficacy of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping.
Topline Results from Phase 1/2 DELIVER Trial in Exon 51 Skip Amenable DMD
March 5, 2026 | 1PM ET | via Zoom
Guest Speaker:
Dr. Doug Kerr, M.D., Ph.D., MBA , is the Chief Medical Officer at Dyne Therapeutics. He is a neuroscientist and neurologist by training with a ten-year career as a faculty member at the Johns Hopkins School of Medicine before a 20-year career at present in the Boston area creating and serving in a series of biotechnology companies in the genetic disease and neurology/neuromuscular space. Doug has over 130 publications in medical journals many of which involved stem cell transplantation for preclinical models of neurologic disorders. He has led the development of several therapies for neurologic and rare genetic diseases while working in the biotechnology industry. He has participated on the boards and SABs of several non-profit organizations, including the Transverse Myelitis Association, CureSMA and the ALS Association as well as several biotechnology companies including Disarm Therapeutics, Triplet Therapeutics and FAZE Medicines. Doug has been actively involved in gene and cell therapy programs and is on the Scientific Review Panel of the California Institute of Regenerative Medicine.
